Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer
The single arm clinical study is to evaluate the efficacy and safety of an anti-PD-1 antibody (Toripalimab) combined with chemotherapy (docetaxel or nab-Paclitaxel) in patients with advanced gastric cancer who failed first-line treatment.
Gastric Cancer Stage IV
DRUG: Toripalimab|DRUG: Docetaxel|DRUG: nab-paclitaxel
disease control rate, disease control rate，According with RECIST 1.1, At 12 weeks
progression free survival, progression free survival, Up to 12months|Complication Rate, Complication Rate, Up to 12months|overall survival rate, overall survival rate, one year
54 patients who meet the inclusion criteria will receive Docetaxel (60-75mg/m2, every 3 weeks) or nab-Paclitaxel （125mg/m2，every 3 weeks）combined with Toripalimab( 240mg,every 3 weeks）for 4-8 cycles until the disease progresses or intolerable toxicity.